Cervical Cancer Medication Update: HYCAMTIN (Topotecan) Approved in Japan

• November 30, 2015
• 1 min read

Key highlights:

1. The anti-malignant tumor agent HYCAMTIN (topotecan injectable formulation, manufactured by Nippon Kayaku Co., Ltd.) received approval from Japan's Ministry of Health, Labour and Welfare on November 20, 2015 for the treatment of progressive or recurrent cervical cancer.

2. Development of this drug began on December 13, 2010.

For more information: http://www.nipponkayaku.co.jp/information/detail.php?n=20151120_7WPGFA55

Cervical Cancer

• Clinical Trial Medications

  • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
  • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
  • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Lung cancer
• Cervical cancer